leisure time -WSS

leisure time

author：entertainment 2025-09-28 23:56:30 - browse：958

When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech supposed to bounce back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics’ polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

For more on what we cover, here’s the Mojsov story; here’s the latest on BrainStorm; here’s the news on Intercept Pharmaceuticals; here’s more on the biotech market; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Psychedelics group wrestles with new pharma identity
Next article： EPA limits use of carcinogenic gas for sterilizing medical devices

hotspot

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Medicare drug price lawsuits could be good politics for Biden

President Biden's budget: Here's what you might have missed

Prior authorization reform is both possible and imperative

Dana Farber says 6 studies to be retracted and 31 corrected

Steward Health Care Massachusetts hospitals face fiscal disaster

leisure time

leisure time

leisure time

Peter Hotez and the public health issue of online harassment

John Green on his newest strategy for fighting tuberculosis

What does generative AI mean for health care? We asked experts

Microsoft launches AI tool for clinical documentation through Epic

In age of alternative facts, a scholarly course on calling out crap

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Dog Aging Project founders on what lies ahead after losing funding

BioMarin wins approval for gene therapy to treat hemophilia A

HPV vaccine, cervical cancer study delivers historic results

hotspot

Inaction leaves children at risk from dangerous chemotherapy drug

Dog Aging Project founders on what lies ahead after losing funding

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Microsoft launches AI tool for clinical documentation through Epic

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

FDA advisers back CAR

hotspot

leisure time

hotspot

focus